Evidence map›Paper›PMID 26024484›Full record

ArticlePloS one2015

1H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer Drug.

Martina Vermathen, Lydia E H Paul, Gaëlle Diserens, Peter Vermathen, Julien Furrer

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Molecules (Basel, Switzerland) · 2021
    Article
  7. Article
  8. Review
  9. Article
  10. Metabolites · 2019
    Article
  11. NMR-Based Metabolomics in Metal-Based Drug Research.Molecules (Basel, Switzerland) · 2019
    Review
  12. Article
  13. Tools for Enhanced NMR-Based Metabolomics Analysis.Methods in molecular biology (Clifton, N.J.) · 2019
    Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Martina VermathenDepartment of Chemistry and Biochemistry, University of Bern, Bern, Switzerland.
Lydia E H PaulDepartment of Chemistry and Biochemistry, University of Bern, Bern, Switzerland.
Gaëlle DiserensDepartments of Clinical Research and Radiology (AMSM), University of Bern, Bern, Switzerland.
Peter VermathenDepartments of Clinical Research and Radiology (AMSM), University of Bern, Bern, Switzerland.
Julien FurrerDepartment of Chemistry and Biochemistry, University of Bern, Bern, Switzerland.
University of Bern · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1)H high resolution magic angle spinning (HR-MAS) NMR spectroscopy was applied in combination with multivariate statistical analyses to study the metabolic response of whole cells to the treatment with a hexacationic ruthenium metallaprism [1](6+) as potential anticancer drug. Human ovarian cancer cells (A2780), the corresponding cisplatin resistant cells (A2780cisR), and human embryonic kidney cells (HEK-293) were each incubated for 24 h and 72 h with [1](6+) and compared to untreated cells. Different responses were obtained depending on the cell type and incubation time. Most pronounced changes were found for lipids, choline containing compounds, glutamate and glutathione, nucleotide sugars, lactate, and some amino acids. Possible contributions of these metabolites to physiologic processes are discussed. The time-dependent metabolic response patterns suggest that A2780 cells on one hand and HEK-293 cells and A2780cisR cells on the other hand may follow different cell death pathways and exist in different temporal stages thereof.

Indexed as

Antineoplastic AgentsCell Line, TumorDrug Screening Assays, AntitumorHEK293 CellsHumansMagnetic Resonance SpectroscopyMetabolomeNeoplasmsOrganometallic CompoundsRutheniumAntineoplastic AgentsOrganometallic CompoundsRuthenium

Identifiers

PMID26024484
PMCPMC4449131
OpenAlexW1863860196

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.